(Q46566761)

23 December 2017

title

A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study (English)

1 reference

23 December 2017

1 reference

endometrial carcinoma

1 reference

1 reference

Edward C Grendys

1

1 reference

23 December 2017

John A Blessing

series ordinal

2

1 reference

23 December 2017

Robert Burger

series ordinal

3

1 reference

23 December 2017

James Hoffman

series ordinal

4

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

23 December 2017

published in

Gynecologic Oncology

1 reference

23 December 2017

volume

98

1 reference

23 December 2017

issue

2

1 reference

23 December 2017

page(s)

249-253

1 reference

23 December 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from dysoxylum binectariferum : isolation, structure and total synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.05.017

10.1016/J.YGYNO.2005.05.017

7 January 2021

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017